Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.55 Billion CNY | 10.33% |
| 2022 | 10.47 Billion CNY | 13.43% |
| 2021 | 9.23 Billion CNY | 13.46% |
| 2020 | 8.13 Billion CNY | 91.15% |
| 2019 | 4.25 Billion CNY | 60.24% |
| 2018 | 2.65 Billion CNY | 21.45% |
| 2017 | 2.18 Billion CNY | 20.09% |
| 2016 | 1.82 Billion CNY | 92.63% |
| 2015 | 945.56 Million CNY | 45.02% |
| 2014 | 652.02 Million CNY | 58.87% |
| 2013 | 410.41 Million CNY | 46.45% |
| 2012 | 280.24 Million CNY | 42.75% |
| 2011 | 196.32 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 11.03 Billion CNY | -4.9% |
| 2024 Q1 | 11.6 Billion CNY | 0.45% |
| 2024 Q3 | 11.38 Billion CNY | 3.19% |
| 2023 Q3 | 11.07 Billion CNY | 4.65% |
| 2023 Q4 | 11.55 Billion CNY | 4.35% |
| 2023 FY | 11.55 Billion CNY | 10.33% |
| 2023 Q1 | 10.51 Billion CNY | 0.38% |
| 2023 Q2 | 10.58 Billion CNY | 0.65% |
| 2022 Q4 | 10.47 Billion CNY | 2.37% |
| 2022 Q3 | 10.22 Billion CNY | 6.11% |
| 2022 Q2 | 9.64 Billion CNY | 0.13% |
| 2022 FY | 10.47 Billion CNY | 13.43% |
| 2022 Q1 | 9.62 Billion CNY | 4.28% |
| 2021 Q1 | 8.06 Billion CNY | -0.85% |
| 2021 Q3 | 8.83 Billion CNY | 4.42% |
| 2021 Q4 | 9.23 Billion CNY | 4.55% |
| 2021 FY | 9.23 Billion CNY | 13.46% |
| 2021 Q2 | 8.45 Billion CNY | 4.82% |
| 2020 Q2 | 4.82 Billion CNY | 1.98% |
| 2020 Q3 | 5.15 Billion CNY | 6.81% |
| 2020 FY | 8.13 Billion CNY | 91.15% |
| 2020 Q4 | 8.13 Billion CNY | 57.99% |
| 2020 Q1 | 4.72 Billion CNY | 11.08% |
| 2019 Q4 | 4.25 Billion CNY | 10.53% |
| 2019 FY | 4.25 Billion CNY | 60.24% |
| 2019 Q3 | 3.85 Billion CNY | 31.89% |
| 2019 Q2 | 2.92 Billion CNY | 2.52% |
| 2019 Q1 | 2.84 Billion CNY | 7.21% |
| 2018 Q2 | 2.24 Billion CNY | -3.19% |
| 2018 Q4 | 2.65 Billion CNY | 8.9% |
| 2018 FY | 2.65 Billion CNY | 21.45% |
| 2018 Q3 | 2.43 Billion CNY | 8.51% |
| 2018 Q1 | 2.32 Billion CNY | 6.17% |
| 2017 Q2 | 1.99 Billion CNY | 3.44% |
| 2017 Q1 | 1.92 Billion CNY | 5.71% |
| 2017 Q3 | 2.02 Billion CNY | 1.63% |
| 2017 Q4 | 2.18 Billion CNY | 8.06% |
| 2017 FY | 2.18 Billion CNY | 20.09% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q3 | 1.71 Billion CNY | 53.05% |
| 2016 Q4 | 1.82 Billion CNY | 6.26% |
| 2016 FY | 1.82 Billion CNY | 92.63% |
| 2016 Q2 | 1.11 Billion CNY | 0.0% |
| 2015 Q1 | 756.74 Million CNY | 0.0% |
| 2015 FY | 945.56 Million CNY | 45.02% |
| 2015 Q4 | 945.56 Million CNY | 0.0% |
| 2015 Q2 | 756.74 Million CNY | 0.0% |
| 2015 Q3 | - CNY | -100.0% |
| 2014 FY | 652.02 Million CNY | 58.87% |
| 2013 FY | 410.41 Million CNY | 46.45% |
| 2012 FY | 280.24 Million CNY | 42.75% |
| 2011 FY | 196.32 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 14.3 Billion CNY | 19.259% |
| Joinn Laboratories(China)Co.,Ltd. | 10.02 Billion CNY | -15.228% |
| WuXi AppTec Co., Ltd. | 74.26 Billion CNY | 84.442% |
| Thalys Medical Technology Group Inc. | 3.34 Billion CNY | -245.745% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 11.76 Billion CNY | 1.815% |
| Chemclin Diagnostics Co., Ltd. | 1.82 Billion CNY | -534.642% |